Form 4: Vera Therapeutics Executive Sells Shares, Exercises Options

Vera Therapeutics SVP of Finance and Chief Accounting Officer Joseph R. Young reported the sale of 15,000 Class A Common Stock shares and the exercise of options for 10,000 shares.

Summary

• Joseph R. Young, SVP, Finance, Chief Accounting Officer of Vera Therapeutics, Inc., reported transactions involving the company's Class A Common Stock.
• Sold 15,000 shares of Class A Common Stock at a weighted-average price of $29.0583 per share on November 11, 2025.
• Acquired 10,000 shares of Class A Common Stock by exercising stock options at an exercise price of $3.9396 per share on November 13, 2025.
• The sale transaction was conducted pursuant to a Rule 10b5-1(c) plan.
• Following these transactions, Joseph R. Young directly beneficially owns 57,839 shares of Class A Common Stock.
• The reported beneficial ownership includes 893 ordinary shares acquired through the Company's 2021 Employee Stock Purchase Plan.
• Remaining derivative securities (stock options) beneficially owned after the reported transactions are 48,589.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (stock sale and option exercise) by a senior executive, conducted under a pre-arranged 10b5-1 plan. These transactions are generally considered neutral in terms of company-specific sentiment as they often relate to personal financial planning rather than a direct signal about the company's immediate prospects.

Positives

• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating pre-scheduled, non-discretionary trades for personal financial management.
• The exercise of stock options at a significantly lower price than the current market price allows the executive to realize value from their compensation.

Negatives

• A senior executive sold 15,000 shares of Class A Common Stock, which could be perceived by some investors as a reduction in insider conviction, despite being pre-planned.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May observe a reduction in direct equity ownership by a key executive, though this is mitigated by the pre-arranged 10b5-1 plan.

Key Dates

Recommendation

This Form 4 details routine insider transactions by a senior executive, including a sale and an option exercise, both conducted under a pre-arranged 10b5-1 plan. Such transactions are generally for personal financial management and do not typically signal a change in the company's fundamental outlook or warrant an immediate change in investment recommendation. Investors should continue to 'hold' and monitor broader company performance and market conditions.

Keywords

Vera Therapeutics, VERA, Insider Trading, Form 4, Stock Sale, Option Exercise, Joseph R. Young, Executive Compensation, Rule 10b5-1